Zibelman, Matthew http://orcid.org/0000-0003-1475-6477
MacFarlane, Alexander W. IV
Costello, Kimberly
McGowan, Thomas
O’Neill, John
Kokate, Rutika http://orcid.org/0000-0002-2932-3570
Borghaei, Hossein http://orcid.org/0000-0002-2577-4454
Denlinger, Crystal S.
Dotan, Efrat
Geynisman, Daniel M.
Jain, Angela
Martin, Lainie
Obeid, Elias
Devarajan, Karthik
Ruth, Karen
Alpaugh, R. Katherine
Dulaimi, Essel Al-Saleem
Cukierman, Edna http://orcid.org/0000-0002-1452-9576
Einarson, Margret
Campbell, Kerry S.
Plimack, Elizabeth R. http://orcid.org/0000-0002-7618-0744
Funding for this research was provided by:
Horizon Pharma
Article History
Received: 29 August 2022
Accepted: 6 July 2023
First Online: 27 July 2023
Competing interests
: M.Z.: Institutionally directed research funding from Horizon Therapeutics and Bristol-Myers Squibb; Advisory Board Honorarium from Horizon Therapeutics. K.S.C.: Advisory Board Honorarium from Horizon Therapeutics, institutionally-directed research funding from Bristol-Myers Squibb. E.R.P.: Advisory Board Honorarium from Horizon Therapeutics. H.B.: research support (clinical trials) from BMS, Lilly, Amgen; Advisory Board/Consultant for BMS, Lilly, Genentech, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, Astra Zeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Da Volterra, Puma, BerGenBio, Bayer, Iobiotech; Data and Safety Monitoring Board for University of Pennsylvania (CAR T Program), Takeda, Incyte, Novartis, Springworks; employment at Fox Chase Cancer Center; Scientific Advisory Board for Sonnetbio (stock options), Inspirna (formerly Rgenix, stock options), Nucleai (stock options); honoraria from Amgen, Pfizer, Daiichi, Regeneron; travel support from Amgen, BMS, Merck, Lilly, EMD-Serono, Genentech, Regeneron. The remaining authors declare no competing interests.